Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.53 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CD38 | P28907 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6424004 | 0.83 | PDCD1 (0.64) | PDCD1CD274CYP1A2CYP2A6 | |
| SCHEMBL31396692 | 0.82 | CD274 (0.65) | PDCD1CD274LMNAHPGDALOX12 | |
| SCHEMBL79911 | 0.79 | ALDH1A1 (0.41) | PDCD1CD274ALDH1A1LMNAHPGD | |
| SCHEMBL18507940 | 0.79 | PDCD1 (0.41) | PDCD1CD274ALDH1A1LMNAHPGD | |
| SCHEMBL3789998 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDALOX12PNMT | |
| SCHEMBL3119523 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAHPGDALOX12PNMT | |
| SCHEMBL9784664 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDALOX12PNMT | |
| SCHEMBL5066645 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDALOX12PNMT | |
| SCHEMBL724659 | 0.77 | ALDH1A1 (0.46) | ALDH1A1LMNAHPGDALOX12PNMT | |
| SCHEMBL1636099 | 0.77 | PNMT (0.64) | ALDH1A1LMNAHPGDALOX12PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111886219-B | Immunosuppressant, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-111886219-A | Immunosuppressant, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | NUVATION BIO INC. (US) | 2020-10-20 | — | — | US | disclosed |
| WO-2020011209-A1 | IMMUNOSUPPRESSIVE AGENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011209-A1 | IMMUNOSUPPRESSIVE AGENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2020-01-16 | — | — | WO | disclosed |
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-4537720-A | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamino)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4477660-A | 7-(S)-Acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-10-16 | — | — | US | disclosed |
| US-4474879-A | Process for 3-hydroxymethyl cephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| US-4459405-A | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| EP-0109816-A1 | N-substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-05-30 | — | — | EP | disclosed |
| EP-0109301-A2 | 7-(S)-acylaminocephalosporin sulfones and process | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| EP-0109300-A2 | Desacetylcephalosporin sulfones | ELI LILLY AND COMPANY (US) | 1984-05-23 | — | — | EP | disclosed |
| US-4436596-A | N-Substituted-2-(R)-(sulfinic acid)-3-(S)-(acylamido)-4-oxo-azetidines and process | ELI LILLY AND COMPANY (US) | 1984-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106436-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | PDCD1 696/4885CD274 1944/4885ALDH1A1 2869/4885 |
| US-10807994-B2 | Heterocyclic compounds and uses thereof | WEE1, WEE2, CCNE1 | PDCD1 1769/4885CD274 3391/4885ALDH1A1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.